Overview

Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis Enhance Chemical Pleurodesis

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Prospective Randomized Double-Blind Controlled Trial of Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis versus Standard of care Talc therapy in patients with recurrent pleural effusion.
Phase:
Phase 4
Details
Lead Sponsor:
Memorial Healthcare System
Collaborator:
Genentech, Inc.
Treatments:
Tissue Plasminogen Activator